Bellicum Pharma (BLCM) Posts Q4 GAAP Loss of $18.99/Share

Bellicum Pharma (NASDAQ: BLCM) reported Q4 EPS of ($18.99), which may not compare with the analyst estimate of ($0.37). Revenue for the quarter came in at $0 versus the consensus estimate of $600 thousand.

The higher net loss amounts for the 2014 periods were due primarily to a charge of $43.2 million incurred in the fourth quarter of 2014 in conjunction with the ARIAD license restructure transaction and a non-cash accounting charge of $24.4 million recorded for the change in fair value of warrants that were exercised in conjunction with Bellicum’s December IPO, of which $23.2 million was a fourth quarter expense.

For earnings history and earnings-related data on Bellicum Pharma (BLCM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• SanDisk upgraded at JPMorgan after investor day; shares climb